![Michael Cassano](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Michael Cassano
Former positions of Michael Cassano
Companies | Position | Start | End |
---|---|---|---|
Orasi Medical, Inc.
![]() Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Chief Tech/Sci/R&D Officer | 20/04/2009 | 18/08/2012 |
JOHN WILEY & SONS, INC. | Corporate Officer/Principal | - | - |
Training of Michael Cassano
University of Minnesota | Masters Business Admin |
Statistics
International
United States | 4 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectoral
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
JOHN WILEY & SONS, INC. | Consumer Services |
Private companies | 1 |
---|---|
Orasi Medical, Inc.
![]() Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
- Stock Market
- Insiders
- Michael Cassano
- Experience